Atlas Trials

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Clinical trial NCT06279364 · RECRUITING

Trial details

NCT number
NCT06279364
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2024-02-28
Primary completion
2026-07-01
Enrollment
524

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.